Coupled with paclitaxel.

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer Amgen today announced that AMG 386, coupled with paclitaxel, demonstrated antitumor activity in a randomized Stage 2 trial involving 161 patients with recurrent ovarian malignancy. AMG 386 is usually a first-in-course investigational peptibody that is designed to block angiogenesis by inhibiting angiopoietin-1 and -2 . The truth of ovarian tumor is definitely that 80 % of females diagnosed in later levels will experience recurrence, multiple times often, and die from the disease eventually, said Beth Karlan, M.D., director of the Women’s Cancer Study Institute at Cedars-Sinai’s Samuel Oschin Comprehensive Cancers Institute and director of Cedars-Sinai Medical Center’s Division of Gynecologic Oncology.